TITLE

Diversity, Drug Resistance, and the Epidemic of Subtype C HIV-1 in Africa

AUTHOR(S)
Katzenstein, David
PUB. DATE
September 2006
SOURCE
Journal of Infectious Diseases;9/16/2006, Vol. 194, pS45
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS) epidemic has grown from a handful of sentinel observations in New York and California, nearly 25 years ago, to an epidemic that has claimed 500,000 lives in the United States and 120 million worldwide. Tom Merigan's scientific career led him to focus on viral pathogenesis as translational ‘bench to-bedside’ research, aimed squarely at the development of antiretroviral treatment. As a founder and leader of the AIDS Clinical Trials Group, Tom played a pivotal role in the national response to HIV. He led the development of a succession of antiretroviral drugs, their combined use, and the introduction of new methods for monitoring HIV infection. The current response to the global epidemic and the tools now coming to bear on diagnosis, treatment, and monitoring owe much to Tom's relentless pursuit of excellence in research and the training he offered generations of clinical virologists and infectious disease physicians.
ACCESSION #
22316929

 

Related Articles

  • HIV-1 Load Quantitation: A 17-Year Perspective. Holodniy, Mark // Journal of Infectious Diseases;9/16/2006, Vol. 194, pS38 

    During the past decade and a half, quantitation of plasma-associated human immunodeficiency virus type 1 (HIV-1) RNA level, or HIV-1 load, has been validated in clinical practice and clinical trials as an important surrogate marker of HIV-1 disease progression and of the potency and durability...

  • Twenty five years of HIV infection in haemophilic men in Britain: an observational study.  // BMJ: British Medical Journal (International Edition);10/29/2005, Vol. 331 Issue 7523, p997 

    The article reflects on the results of a 25 year observational study of HIV in haemophilic men in the United Kingdom. The author reviews the introduction of highly active antiretroviral therapy (HAART). The article analyzes various statistical data related to the study. According to the author,...

  • Asistencia mensual a la clínica de virus de inmunodeficiencia adquirida por receta resurtible y adherencia al tratamiento antirretroviral. Zonana-Nacach, Abraham; Torres-Salinas, Samantha; Franco-Esquivel, Sonia Judith // Salud Pública de México;sep/oct2014, Vol. 56 Issue 5, p423 

    No abstract available.

  • HIV-1 Reverse Transcriptase: A Therapeutical Target in the Spotlight. Castro, H. C.; Loureiro, N. I.V.; Pujol-Luz, M.; Souza, A. M.T.; Albuquerque, M. G.; Santos, D. O.; Cabral, L. M.; Frugulhetti, I. C.; Rodrigues, C. R. // Current Medicinal Chemistry;2006, Vol. 13 Issue 3, p313 

    Human Immunodeficiency Virus type 1 Reverse Transcriptase (HIV-1 RT) is one of the most important targets for treatment of Acquired Immune Deficiency Syndrome (AIDS). It catalyzes the reverse transcription of HIV-RNA into a double stranded DNA, and the knowledge of its substrate specificity and...

  • Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. Savarino, Andrea; Pistello, Mauro; D'Ostilio, Daniela; Zabogli, Elisa; Taglia, Fabiana; Mancini, Fabiola; Ferro, Stefania; Matteucci, Donatella; De Luca, Laura; Barreca, Maria Letizia; Ciervo, Alessandra; Chimirri, Alba; Ciccozzi, Massimo; Bendinelli, Mauro // Retrovirology;2007, Vol. 4, p79 

    Background: Treatment of feline immunodeficiency virus (FIV) infection has been hampered by the absence of a specific combination antiretroviral treatment (ART). Integrase strand transfer inhibitors (INSTIs) are emerging as a promising new drug class for HIV-1 treatment, and we evaluated the...

  • The Nutritional Status of Children and Adolescents with HIV/AIDS on Antiretroviral Therapy. Souza, Déborah Teixeira; Rondó, Patrícia Helen Carvalho; Reis, Ligia Cardoso // Journal of Tropical Pediatrics;Feb2011, Vol. 57 Issue 1, p65 

    The objective of this cross-sectional study was to assess the nutritional status of children and adolescents with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) receiving highly active antiretroviral therapy (HAART). One hundred and eighteen subjects aged 6–19...

  • Mitochondrial Disorders among Infants Exposed to HIV and Antiretroviral Therapy. Funk, Michele Jonsson; Belinson, Suzanne E.; Pimenta, Jeanne M.; Morsheimer, Megan; Gibbons, David C. // Drug Safety;2007, Vol. 30 Issue 10, p845 

    Although antiretroviral therapy (ART) is critical for preventing mother-to-child transmission of HIV, concern has been raised about the possibility that it may cause mitochondrial dysfunction in infants. There is adequate evidence for a mechanism by which exposure to nucleoside reverse...

  • Profile: David Ho. Mandavilli, Apoorva // Nature Medicine;Nov2004, Vol. 10 Issue 11, p1150 

    The article focuses on the work of researcher David Ho. Ho is perhaps best known for showing in 1996 that combining anti-retroviral drugs can drive HIV down to undetectable levels. The finding made a splash at that year's International AIDS Conference in Vancouver. Among scientists, Ho is more...

  • The Setpoint Study (ACTG A5217): Effect of Immediate Versus Deferred Antiretroviral Therapy on Virologic Set Point in Recently HIV-1-Infected Individuals. Hogan, Christine M.; DeGruttola, Victor; Sun, Xin; Fiscus, Susan A.; Rio, Carlos Del; Hare, C. Bradley; Markowitz, Martin; Connick, Elizabeth; Macatangay, Bernard; Tashima, Karen T.; Kallungal, Beatrice; Camp, Rob; Morton, Tia; Daar, Eric S.; Little, Susan // Journal of Infectious Diseases;1/1/2012, Vol. 205 Issue 1, p87 

    Background. The benefits of antiretroviral therapy during early human immunodeficiency virus type 1 (HIV-1) infection remain unproved. Methods. A5217 study team randomized patients within 6 months of HIV-1 seroconversion to receive either 36 weeks of antiretrovirals (immediate treatment [IT]) or...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics